MaxCyte to Present Scalable Clinical and Commercial Manufacturing Technology for Cell-Based and Viral-Based Vaccines
Posted on: Wednesday, 16 July 2008, 12:01 CDT
GAITHERSBURG, Md., July 16 /PRNewswire/ -- MaxCyte, Inc., a clinical-stage therapeutics company and pioneer in clinical scale, non-viral cell loading systems, announces that Madhusudan V. Peshwa, Ph.D., Vice President Research and Development at MaxCyte, will present on Thursday, July 17, 2008 at 4:40PM EDT at IBC's Next Generation Vaccines Conference at Gaylord National Resort & Convention Center in National Harbor, MD. Dr. Peshwa's presentation is entitled, "Scaleable Clinical and Commercial Manufacturing Technology for Next Generation Vaccines" and will discuss how MaxCyte's proprietary technology, which is currently being employed in multiple clinical trials, solves the key issues of: scalability, reproducibility, and commercial feasibility, while having a well accepted regulatory path as well as the ability to improve upon product titer and functional activity. Dr. Peshwa will discuss MaxCyte's validated, regulatory-compliant technology in the context of a manufacturing platform enabling rapid development of robust, scalable cGMP production methods for vaccines, VLPs and viral vectors using various flexible, single-use disposable configurations.
About MaxCyte
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary, non-viral, ex vivo cell loading technology provides safety, scalability and reproducibility capabilities which are fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with Medinet (JP) to commercialize a cell based therapy to be launched in 2008. In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).
For more information, visit http://www.maxcyte.com/.
MaxCyte, Inc.
CONTACT: Anthony Recupero, Ph.D., Vice President Business DevelopmentMaxCyte, Inc., +1-301-944-1700
Web Site: http://www.maxcyte.com/
Source: PRNewswire
Related Articles
- MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
- AlphaVax Initiates Chlamydia Vaccine Program
- AlphaVax Announces Initiation of Chlamydia Vaccine Program
- Vivalis Licenses EBx Cell Line for Production of Viral Vaccines
- Novavax Announces Favorable Interim Results From Human Clinical Trial for Its Pandemic Influenza Vaccine Program
- CORRECTING and REPLACING DOR BioPharma Awarded Two Grants Totaling $5.3 Million to Advance Ricin Toxin and Botulinum Toxin Vaccine Programs
- Serono and Rigel Sign Agreement to Develop and Commercialize Aurora Kinase Inhibitors
- Cell Genesys Confirms Upcoming Clinical Data Presentations for Two GVAX(R) Cancer Vaccine Programs
- Agensys and Merck Announce Agreement to Co-Develop and Commercialize a Novel Antibody for Cancer Therapy
- Cytogen Corporation Provides QUADRAMET(R) Clinical Development and Commercialization Update
 |
 |
User Comments (0)
RSS Feeds